scholarly journals Angiotensin‐converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta‐analysis

2021 ◽  
Author(s):  
P. Donati ◽  
A. Tarducci ◽  
R. Zanatta ◽  
N. Verdier ◽  
G. Belerenian ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mitral Valve ◽  
Angiotensin Converting Enzyme ◽  
Mitral Valve Disease ◽  
Enzyme Inhibitors ◽  
Meta Analysis ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Valve Disease ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

Angiotensin converting enzyme inhibitors use and development of lung cancer: A systematic review and meta-analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13093-e13093 ◽  
Author(s):  
Waled Bahaj ◽  
Anas Albawaliz ◽  
Aref Qureini ◽  
Omar Khaled Mahmoud Abughanimeh ◽  
Moustafa Younis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Relative Risk ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Meta Analysis ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Care Providers ◽  
Converting Enzyme Inhibitors

e13093 Background: Angiotensin-converting enzyme inhibitors (ACEIs) are commonly prescribed medications for hypertension and heart failure. Generally, ACEIs are well-tolerated medications with reasonable safety profile making them a favorable choice by many clinicians. However, several studies with conflicting results have signaled an association between ACEIs use and the development of lung cancer. We sought to systematically review the literature and perform the first meta-analysis to study the risk of lung cancer among ACEI users. Methods: We performed a literature review by searching multiple databases. A random effect meta-analysis approach was used to pool the data and relative risk was used to calculate the overall effect estimate. Results: A total of 423 articles were identified but only 6 observational studies were included with a total of 872,220 patients (634,672. ACEIs users). The relative risk of lung cancer development among ACEIs users was 1.02 (CI 0.89-1.16) compared to non-ACEIs users. Conclusions: Current systematic review and meta-analysis show no significant association between ACEIs use and the development of lung cancer. The result of our meta-analysis provides further assurance to the health care providers regarding ACEIs use.

Sign in / Sign up

Export Citation Format

Share Document